Skip to content
Boca Raton City Online – Lifestyle
Author:
TORL Biotherapeutics LLC
TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026
June 18, 2026